Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan
Authors
Keywords
-
Journal
Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
Volume Volume 14, Issue -, Pages 773-781
Publisher
Informa UK Limited
Online
2021-02-22
DOI
10.2147/dmso.s289446
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Expected and paradoxical effects of obesity on cancer treatment response
- (2020) Marco Gallo et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
- (2019) Ken Kato et al. LANCET ONCOLOGY
- The Science of Obesity Management: An Endocrine Society Scientific Statement
- (2018) George A Bray et al. ENDOCRINE REVIEWS
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer
- (2018) Guido Eibl et al. Journal of the Academy of Nutrition and Dietetics
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- A review of guidelines for lung cancer
- (2018) Paolo Bironzo et al. Journal of Thoracic Disease
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- Survival Impact of Delaying Postoperative Radiotherapy in Patients with Esophageal Cancer
- (2018) Yuanyuan Wang et al. Translational Oncology
- Prognostic Factors and Survival of Gliomatosis Cerebri: A Systematic Review and Meta-Analysis
- (2018) Marios K. Georgakis et al. World Neurosurgery
- Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
- (2018) Biagio Ricciuti et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know)
- (2018) R. M. Ruggeri et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
- (2017) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies
- (2017) David J. Byun et al. Nature Reviews Endocrinology
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Pre-existing diabetes and lung cancer prognosis
- (2016) Juhua Luo et al. BRITISH JOURNAL OF CANCER
- Increasing Number of People with Diabetes in Japan: Is This Trend Real?
- (2016) Atsushi Goto et al. INTERNAL MEDICINE
- Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy
- (2016) Gadi Shlomai et al. JOURNAL OF CLINICAL ONCOLOGY
- NICE guidance on ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
- (2016) Caroline J Hall et al. LANCET ONCOLOGY
- NICE guidance on necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
- (2016) Nwamaka Umeweni et al. LANCET ONCOLOGY
- The Effect of Diabetes Mellitus on Lung Cancer Prognosis
- (2016) Linhai Zhu et al. MEDICINE
- Management of advanced medullary thyroid cancer
- (2016) Julien Hadoux et al. Lancet Diabetes & Endocrinology
- De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells
- (2014) Luciana Berod et al. NATURE MEDICINE
- Diabetes and Cancer: A consensus report
- (2010) E. Giovannucci et al. DIABETES CARE
- Overview of the immune response
- (2010) David D. Chaplin JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Diabetes and cancer
- (2009) Paolo Vigneri et al. ENDOCRINE-RELATED CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More